Across 106 Phase II and Phase III inflammatory bowel disease trials authorized in 2024–2026, the EU site network is broad but operationally concentrated around a smaller group of repeat IBD centers. Medical Network Sp. z o.o. was the most active identified site with 12 trial-site records, followed by Gastromed Sp. z o.o. with 8 and Area Sanitaria De Ferrol with 7. Phase III represented 56 of 106 trials, while participant allocation was most concentrated in Poland, Spain, France, Italy, and Germany.
The 10 most active identified EU IBD sites together accounted for 59 trial-site records. The top site, Medical Network Sp. z o.o., appeared in 12 records, equal to 20.3% of the top-10 site-record total.
The top-ranking sites are not only large academic hospitals. Poland’s recurring private or specialist IBD networks indicate that sponsor site strategy in IBD relies heavily on high-throughput outpatient research infrastructure as well as university gastroenterology centers.
Phase III trials accounted for 56 of 106 trials, or 52.8%, while Phase II accounted for 50 of 106 trials, or 47.2%. By authorization year, 2024 contributed 58 of 106 trials, followed by 33 in 2025 and 15 in 2026.
The near-even Phase II/III split suggests that IBD site feasibility is relevant across both proof-of-concept and confirmatory development, rather than being concentrated only in late-stage programs.
The top 10 countries accounted for 4,181 allocated participants across country records. Poland ranked first with 904 participants, followed by Spain with 704 and France with 684.
| Country | Participants | Top-10 share |
|---|---|---|
| Poland | 904 | 21.6% |
| Spain | 704 | 16.8% |
| France | 684 | 16.4% |
| Italy | 532 | 12.7% |
| Germany | 443 | 10.6% |
| Czechia | 369 | 8.8% |
| Hungary | 318 | 7.6% |
| Netherlands | 291 | 7.0% |
| Belgium | 266 | 6.4% |
| Bulgaria | 253 | 6.1% |
The country pattern reflects a mixed model: Poland contributes high-volume specialist networks, Spain contributes repeat hospital-based IBD sites, and France contributes large multicenter hospital allocations.
Disease records were concentrated in ulcerative colitis, Crohn’s disease, and mixed IBD populations. Ulcerative colitis accounted for 46 of 106 trials, Crohn’s disease for 34, and mixed IBD or combined UC/Crohn’s populations for 26.
The disease mix suggests that EU IBD trial infrastructure must support both disease-specific recruitment and broader IBD platforms. UC remains the largest single indication, but mixed IBD records are large enough to matter operationally.
IBD means inflammatory bowel disease. UC means ulcerative colitis. Crohn’s disease refers to Crohn’s disease trial populations. A trial-site record means one site appearing as a participating site in one trial record; repeated appearances across trials indicate recurring participation.